Stock Chart

REPL

$15.22 -0.51%
Score: 33.5 SELL
LEAPs: SELL $12
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $12
Premium: $3.55
Expiry: Jan 15, 2027
Target: $13
Score: -76

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $15.3 - $17.85 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.84
Vol: 0.10x (vs SPY: 0.3x | vs QQQ: 0.2x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About REPL - Replimune Group, Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its …

Key Statistics

Market Cap $1B

This REPL stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track REPL's price movements with trendlines, gamma walls, and key support/resistance levels.